Business Description
GT Biopharma Inc
NAICS : 325412
SIC : 2834
ISIN : US6918295014
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 326.9 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.01 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 68.3 | |||||
3-Year EPS without NRI Growth Rate | 60.5 | |||||
3-Year FCF Growth Rate | 49.2 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
9-Day RSI | 26.37 | |||||
14-Day RSI | 31.27 | |||||
6-1 Month Momentum % | -22.82 | |||||
12-1 Month Momentum % | -45.17 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.15 | |||||
Quick Ratio | 2.15 | |||||
Cash Ratio | 2.13 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -99.5 | |||||
Shareholder Yield % | 1.56 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -101.2 | |||||
ROA % | -61.45 | |||||
ROIC % | -2814.29 | |||||
ROC (Joel Greenblatt) % | -11442.99 | |||||
ROCE % | -90.63 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.85 | |||||
Price-to-Tangible-Book | 0.85 | |||||
EV-to-EBIT | 0.31 | |||||
EV-to-EBITDA | 0.31 | |||||
EV-to-FCF | 0.27 | |||||
Price-to-Net-Current-Asset-Value | 0.86 | |||||
Price-to-Net-Cash | 0.87 | |||||
Earnings Yield (Greenblatt) % | 325.21 | |||||
FCF Yield % | -148.75 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
GT Biopharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -6.4 | ||
Beta | 0.2 | ||
Volatility % | 38.15 | ||
14-Day RSI | 31.27 | ||
14-Day ATR (€) | 0.000308 | ||
20-Day SMA (€) | 4.77 | ||
12-1 Month Momentum % | -45.17 | ||
52-Week Range (€) | 4.77 - 10.74 | ||
Shares Outstanding (Mil) | 2.16 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
GT Biopharma Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
GT Biopharma Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
GT Biopharma Inc Frequently Asked Questions
What is GT Biopharma Inc(FRA:OXIA)'s stock price today?
When is next earnings date of GT Biopharma Inc(FRA:OXIA)?
Does GT Biopharma Inc(FRA:OXIA) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |